Post-Authorisation Safety Study (PASS) to Evaluate the Risk of Malignancies in Patients with Myasthenia Gravis (MG) Treated with Efgartigimod First published 03/02/2026 Last updated 03/02/2026 EU PAS number:EUPAS1000000915 Study Planned